NASDAQ : TGTX
TG Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 61.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 8.68B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.50B |
| Enterprise Value | 8.71B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 141.85M |
| Shares Outstanding | 141.85M |
| Shares Change (YoY) | -5.56% |
| Shares Change (QoQ) | -1.74% |
| Owned by Insiders (%) | 4.62% |
| Owned by Institutions (%) | 83.48% |
| Float | 135.24M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 21.65 |
| Forward PE | 31.27 |
| PS Ratio | 10.64 |
| Forward PS | 7.68 |
| PB Ratio | 14.08 |
| P/TBV Ratio | 14.08 |
| P/FCF Ratio | 489.15 |
| P/OCF Ratio | 475.71 |
| PEG Ratio | 1.39 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 19.72 |
| EV / Sales | 10.89 |
| EV / EBITDA | 63.80 |
| EV / EBIT | 63.86 |
| EV / FCF | 500.78 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.27 |
| Quick Ratio | 3.55 |
| Debt / Equity | 1.25 |
| Debt / EBITDA | 5.45 |
| Debt / FCF | 43.40 |
| Interest Coverage | 3.64 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 100.28% |
| Return on Assets (ROA) | 7.28% |
| Return on Invested Capital (ROIC) | 16.74% |
| Return on Capital Employed (ROCE) | 9.94% |
| Weighted Average Cost of Capital (WACC) | 13.31% |
| Revenue Per Employee | $2.00M |
| Profits Per Employee | $1.11M |
| Employee Count | 399 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 0.93 |
Taxes
| Measure | Value |
|---|
| Income Tax | -339.89M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.80 |
| 52-Week Price Change | +72.37% |
| 50-Day Moving Average | 55.44 |
| 200-Day Moving Average | 43.95 |
| Relative Strength Index (RSI) | 64.27 |
| Average Volume (20 Days) | 1,589,046 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 29.59M |
| Short Previous Month | 30.63M |
| Short % of Shares Out | 20.86% |
| Short % of Float | 21.88% |
| Short Ratio (days to cover) | 16.22 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 799.54M |
| Gross Profit | 658.60M |
| Operating Income | 136.33M |
| Pretax Income | 101.60M |
| Net Income | 441.49M |
| EBITDA | 136.45M |
| EBIT | 136.33M |
| Earnings Per Share (EPS) | $2.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 552.25M |
| Total Debt | 754.44M |
| Net Cash | -202.19M |
| Net Cash Per Share | -$1.43 |
| Equity (Book Value) | 604.08M |
| Book Value Per Share | 4.26 |
| Working Capital | 877.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 17.88M |
| Capital Expenditures | -491,000 |
| Depreciation & Amortization | 123,000 |
| Net Borrowing | 492.66M |
| Free Cash Flow | 17.39M |
| FCF Per Share | $0.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | 82.37% |
| Operating Margin | 17.05% |
| Pretax Margin | 12.71% |
| Profit Margin | 55.22% |
| EBITDA Margin | 17.07% |
| EBIT Margin | 17.05% |
| FCF Margin | 2.17% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 5.56% |
| Shareholder Yield | 5.56% |
| Earnings Yield | 4.62% |
| FCF Yield | 0.20% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $69.71 |
| Price Target Difference | 16.28% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 38.17% |
| EPS Growth Forecast (3Y) | 6.06% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:56.25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.37 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |